Necrolytic Acral Erythema: A Review of the Literature
This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: May 2009.
Mr. Geria, Dr. Holcomb, and Dr. Scheinfeld report no conflict of interest. The authors discuss off-label use of interferon alfa, oral zinc sulfate, and ribavirin. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Mr. Geria is a medical student, New Jersey Medical School, Newark. Dr. Holcomb is staff dermatologist, National Capital Corsortium Residency Program, National Naval Medical Center, Bethesda, Maryland, and Walter Reed Army Medical Center, Washington, DC. Dr. Scheinfeld is Assistant Attending, St. Luke's-Roosevelt Hospital Center, New York, New York, and Assistant Clinical Professor of Dermatology, Columbia University, New York.
Aanand N. Geria, BS; Katherine Z. Holcomb, MD, MSPH; Noah S. Scheinfeld, MD, JD
Necrolytic acral erythema (NAE) has been described as an early cutaneous marker for hepatitis C virus (HCV) infection. It most commonly presents as a well-defined, dusky, erythematous eruption with marked hyperkeratosis and a dark red rim associated with pruritus or burning. Necrolytic acral erythema bears microscopic and clinical resemblance to other necrolytic erythemas, including necrolytic migratory erythema (NME) and several nutrient-deficient syndromes. It is distinct, however, in its predominantly acral distribution and strong association with HCV infection. The pathogenesis is unknown, but a relationship to metabolic alterations has been hypothesized. Optimal therapy appears to be treatment of the underlying HCV infection using a combination of ribavirin and interferon alfa; oral zinc therapy may be an alternative but useful therapy. Cases of NAE without HCV infection suggest that more work needs to be done defining NAE and its relationship to HCV.